Vision-Sciences (VSCI) 0.35 $VSCI
Cogentix Medical Reports Fourth Quarter and Full Year Fiscal 2015 Results
PR Newswire - Thu May 14, 3:01PM CDT
Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device company with innovative and proprietary products serving urology and airway management markets, today announced results for the fiscal fourth quarter and full year ended March 31, 2015.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03), CGNT: 1.09 (-0.01)
Uroplasty and Vision-Sciences Complete Merger
PR Newswire - Tue Mar 31, 3:00PM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) today announced the completion of their merger. The merger was originally announced in December 2014, and completion of the all-stock combination creates a new medical device company named Cogentix Medical, Inc. Beginning on April 1, 2015, Cogentix Medical, Inc. will trade on the NASDAQ under the symbol CGNT. Cogentix Medical will have its U.S. headquarters in Minnetonka, MN, where Uroplasty's current headquarters is located.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Vision-Sciences, Inc. Announces 1:5 Reverse Stock Split
ACCESSWIRE - Tue Mar 31, 12:57PM CDT
ORANGEBURG, NY / ACCESSWIRE / March 31, 2015 / Following the shareholders meeting of Vision-Sciences, Inc. (NASDAQ: VSCI) (the "Company"
on March 30, 2015, the Company's board of directors determined to effect a one-for-five reverse stock split of the Company's common stock effective at 4:05 pm EDT on March 31, 2015.
VSCI: 0.35 (-0.02)
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement
PR Newswire - Mon Mar 30, 10:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) shareholders have voted at the special meeting of each company's shareholders held today to approve the previously announced agreement and plan of merger between the two companies.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015
Marketwired - Wed Feb 04, 3:15PM CST
Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider of unique flexible endoscopic products, today announced financial results for the three- and nine-month periods ended December 31, 2014.
VSCI: 0.35 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of Vision-Sciences, Inc. In Connection With the Fairness of the Merger of the Company to Uroplasty, Inc.
BusinessWire - Mon Feb 02, 2:57PM CST
Levi & Korsinsky is commencing an investigation into the Board of Directors of Vision-Sciences, Inc. ("Vision-Sciences" or "the Company" (NasdaqCM:VSCI) in connection with possible breaches of fiduciary duty and other violations of state law in connection with the merger of the Company to Uroplasty, Inc. (NasdaqCM:UPI).
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Vision-Sciences to Host Third Quarter Fiscal 2015 Results Call
ACCESSWIRE - Thu Jan 22, 7:00AM CST
ORANGEBURG, NY / ACCESSWIRE / January 22, 2015 / Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the third quarter fiscal 2015, ended December 31, 2014, after the market closes on Wednesday, February 4, 2015. Howard Zauberman, President and Chief Executive Officer, and Gary Siegel, Vice President, Finance, will host a conference call to discuss the results as follows:
VSCI: 0.35 (-0.02)
UPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. - UPI
BusinessWire - Wed Dec 31, 11:33AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Uroplasty, Inc. (NasdaqCM:UPI) ("Uroplasty" in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM:VSCI).
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
New Research Study by the Mayo Clinic Finds Sedation-Free TNE With EndoSheath(R) Technology May Provide an Effective Alternative to Standard Upper Endoscopy Procedures
GlobeNewswire - Mon Dec 29, 6:30AM CST
A new peer-reviewed research study published in the American Journal of Gastroenterology concludes sedation-free transnasal esophagoscopy (TNE) may provide an effective alternative strategy to conventional sedated esophagogastroduodenoscopy (EGD) for esophageal assessment and Barrett's Esophagus (BE) screening for patients. The research trial was conducted by gastroenterologists at the Mayo Clinic utilizing the Vision Sciences Transnasal Esophagoscope with EndoSheath Technology and evaluated over 200 patients in both a clinic setting and in the community as part of the health system's mobile research program.
VSCI: 0.35 (-0.02)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
BusinessWire - Wed Dec 24, 11:19AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company" (NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI).
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03), CGNT: 1.09 (-0.01)
UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Vision-Sciences, Inc.
BusinessWire - Tue Dec 23, 10:40AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Uroplasty, Inc. ("Uroplasty" (NASDAQ: UPI) concerning the sale to Vision-Sciences, Inc. (NasdaqCM: VSCI). Under the terms of the agreement, Uroplasty shareholders will receive 3.6331 shares of VSCI for each share owned. Based on the closing price of both stocks before the deal was announced, the consideration is valued at approximately $3.67, which is only a 15.6% premium and significantly lower than the 52-week high. Also, at least one analyst estimated a value of $6.00 per share.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Cogentix Medical Reports Fourth Quarter and Full Year Fiscal 2015 Results
PR Newswire - Thu May 14, 3:01PM CDT
Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device company with innovative and proprietary products serving urology and airway management markets, today announced results for the fiscal fourth quarter and full year ended March 31, 2015.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03), CGNT: 1.09 (-0.01)
Uroplasty and Vision-Sciences Complete Merger
PR Newswire - Tue Mar 31, 3:00PM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) today announced the completion of their merger. The merger was originally announced in December 2014, and completion of the all-stock combination creates a new medical device company named Cogentix Medical, Inc. Beginning on April 1, 2015, Cogentix Medical, Inc. will trade on the NASDAQ under the symbol CGNT. Cogentix Medical will have its U.S. headquarters in Minnetonka, MN, where Uroplasty's current headquarters is located.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Vision-Sciences, Inc. Announces 1:5 Reverse Stock Split
ACCESSWIRE - Tue Mar 31, 12:57PM CDT
ORANGEBURG, NY / ACCESSWIRE / March 31, 2015 / Following the shareholders meeting of Vision-Sciences, Inc. (NASDAQ: VSCI) (the "Company"
on March 30, 2015, the Company's board of directors determined to effect a one-for-five reverse stock split of the Company's common stock effective at 4:05 pm EDT on March 31, 2015. VSCI: 0.35 (-0.02)
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement
PR Newswire - Mon Mar 30, 10:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) shareholders have voted at the special meeting of each company's shareholders held today to approve the previously announced agreement and plan of merger between the two companies.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015
Marketwired - Wed Feb 04, 3:15PM CST
Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider of unique flexible endoscopic products, today announced financial results for the three- and nine-month periods ended December 31, 2014.
VSCI: 0.35 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of Vision-Sciences, Inc. In Connection With the Fairness of the Merger of the Company to Uroplasty, Inc.
BusinessWire - Mon Feb 02, 2:57PM CST
Levi & Korsinsky is commencing an investigation into the Board of Directors of Vision-Sciences, Inc. ("Vision-Sciences" or "the Company"
(NasdaqCM:VSCI) in connection with possible breaches of fiduciary duty and other violations of state law in connection with the merger of the Company to Uroplasty, Inc. (NasdaqCM:UPI). VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Vision-Sciences to Host Third Quarter Fiscal 2015 Results Call
ACCESSWIRE - Thu Jan 22, 7:00AM CST
ORANGEBURG, NY / ACCESSWIRE / January 22, 2015 / Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the third quarter fiscal 2015, ended December 31, 2014, after the market closes on Wednesday, February 4, 2015. Howard Zauberman, President and Chief Executive Officer, and Gary Siegel, Vice President, Finance, will host a conference call to discuss the results as follows:
VSCI: 0.35 (-0.02)
UPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. - UPI
BusinessWire - Wed Dec 31, 11:33AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Uroplasty, Inc. (NasdaqCM:UPI) ("Uroplasty"
in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM:VSCI). VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
New Research Study by the Mayo Clinic Finds Sedation-Free TNE With EndoSheath(R) Technology May Provide an Effective Alternative to Standard Upper Endoscopy Procedures
GlobeNewswire - Mon Dec 29, 6:30AM CST
A new peer-reviewed research study published in the American Journal of Gastroenterology concludes sedation-free transnasal esophagoscopy (TNE) may provide an effective alternative strategy to conventional sedated esophagogastroduodenoscopy (EGD) for esophageal assessment and Barrett's Esophagus (BE) screening for patients. The research trial was conducted by gastroenterologists at the Mayo Clinic utilizing the Vision Sciences Transnasal Esophagoscope with EndoSheath Technology and evaluated over 200 patients in both a clinic setting and in the community as part of the health system's mobile research program.
VSCI: 0.35 (-0.02)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
BusinessWire - Wed Dec 24, 11:19AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
(NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI). VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03), CGNT: 1.09 (-0.01)
UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Vision-Sciences, Inc.
BusinessWire - Tue Dec 23, 10:40AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Uroplasty, Inc. ("Uroplasty"
(NASDAQ: UPI) concerning the sale to Vision-Sciences, Inc. (NasdaqCM: VSCI). Under the terms of the agreement, Uroplasty shareholders will receive 3.6331 shares of VSCI for each share owned. Based on the closing price of both stocks before the deal was announced, the consideration is valued at approximately $3.67, which is only a 15.6% premium and significantly lower than the 52-week high. Also, at least one analyst estimated a value of $6.00 per share. VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
